سعر روستاتين ٢٠ مجم ٣٠ أقراص 20 مجم 2026

Atorvastatin 20 mg film-coated tablets (statin), ADWIA, Egypt; 30 tablets. Locally registered and manufactured per Greendol.

• Reduce risk of MI, stroke, revascularization and angina in adults with multiple CHD risk factors or with clinically evident CHD; and in type 2 diabetes with multiple risk factors.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet to reduce LDL-C in primary hyperlipidemia (adults) and HeFH (adults and children >=10 years); adjunct for HoFH, primary dysbetalipoproteinemia and hypertriglyceridemia.Population: Adults; pediatric >=10 years for HeFH/HoFHDailyMed (U.S. National Library of Medicine)
• Primary and secondary prevention of coronary events; primary hypercholesterolemia and mixed dyslipidemia (directory-reproduced indications).Population: Adults

• Most common (>=5%): nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis; hypersensitivity to atorvastatin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk increased with age >=65, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher doses; discontinue if CK markedly elevated or myopathy suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotizing myopathy (rare); hepatic dysfunction with transaminase increases; increases in HbA1c and fasting glucose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Clarithromycin, itraconazole, saquinavir/ritonavir, darunavir/ritonavir, fosamprenavir, elbasvir/grazoprevir, letermovirDo not exceed atorvastatin 20 mg daily (increased myopathy risk).DailyMed (U.S. National Library of Medicine)
• NelfinavirDo not exceed atorvastatin 40 mg daily.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognized (or consider ongoing therapeutic need); may cause fetal harm based on mechanism; observational data have not identified an increased risk of major malformations.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Atorvastatin: Inhibits HMG-CoA reductase, decreasing cholesterol synthesis.